A study to assess efficacy, safety and pharmacokinetics of a tacrolimus new oral formulation (MR4) in de novo bone marrow transplant recipients

Inclusion Criteria:

• Bone marrow transplantation patients aged 20-54 except for transplanted from genetically HLA matched sibling donor.
• The patient had been fully informed.

Exclusion Criteria:

• The patient had severe impaired hepatic function.
• The patient had impaired renal function.
• The patient had existing complication of severe cardiac dysfunction.
• The patient had severe impaired pulmonary function.